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The potential antiamnesic properties of atropine were investigated in the mouse passive avoidance test.
Amnesia was induced by scopolamine (2 mg/kg i.p.) and by exposure to a hypoxic environment (5% O2
in water-saturated nitrogen) for 8 min. Atropine (1–10 mg/kg s.c.) completely prevented disrupted acqui-
sition without improving learning in mice with memory deficiency. At the same doses atropine did not
produce any behavioural side effects in mice. # 1998 John Wiley & Sons, Ltd.
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INTRODUCTION
The central cholinergic system has long been known to be
involved in the modulation of learning and memory
processes in animals and man. Drugs that affect the
central cholinergic system have been found either to
enhance or to hinder performance in learning and
memory tests. Direct muscarinic agonists (oxotremorine,
arecoline, AF-102B, RS 86 etc.) acetylcholine esterase
inhibitors (physostigmine, DFP, eptastigmine, tacrine
etc.) and acetylcholine releasers (AFDX 116, DuP 996,
SM-21 etc.) potentiate test performance retention in
rodents (Bartolini et al., 1994; Coyle, 1995). On the
contrary, disruption of the cholinergic system produces
impairment of cognitive processes. The administration of
muscarinic antagonists (scopolamine, atropine, pirenze-
pine and dicyclomine) or inhibitors of choline uptake
(hemicolinium-3), or lesions of nucleus basalis magno-
cellularis (NBM) or injection of the cholinotoxic agent
AF64A, all induce amnesia (Coyle, 1995). Ghelardini et
al. (1990) reported that the antimuscarinic drug atropine,
in doses ranging from 1 to 10 mg/kg s.c., induced
cholinergic antinociception as evidenced by its preven-
tion by pretreatment with hemicolinium-3, with the M1
antagonists pirenzepine and dicyclomine, and by NBM
lesions. We thought it worthwhile to investigate whether
atropine, in the range of doses in which it produces
antinociception through cholinergic system activation,
was also endowed with antiamnesic properties.
METHODS
Animals. Male albino mice (20–25 g) from Morini (San
Polo d’Enza - Italy) were used. All experiments were
carried out according to the guidelines of the European
Community Council on animal care.
Passive-avoidance test. The test was conducted in a two-
compartment passive avoidance box performed accord-
ing to the step-through method described by Jarvik and
Kopp (1967), and modified for testing drugs endowed
with analgesic properties. The apparatus comprises a
two-compartment acrylic box with a lighted compart-
ment connected to a darkened one by a guillotine door. In
the original method mice received a punishing electrical
shock as soon as they entered the dark compartment,
while in our modified method mice receive a non-painful
punishment consisting of a fall into a cold water bath
(10° C) after their entry into the dark compartment. For
this purpose the dark chamber was constructed with a
pitfall floor. The latency times for entering the dark
compartment were measured in the training test and after
24 h in the retention test. For memory disruption, mice
were: (1) injected with scopolamine (2 mg/kg i.p.)
immediately after termination of the training session;
(2) exposed to a hypoxic environment for 8 min up to 30
before passive avoidance training. The oxygen concen-
tration used was 5.0% in water-saturated nitrogen.
Atropine was injected subcutaneously (s.c.) 20 min
before the training session. The maximum entry latency
allowed in the retention session was 120 s. The degree of
memory of the received punishment (fall into cold water)
was expressed as the difference (D s) between retention
and training latency.
Irwing test. The test was performed according to the
method described by Irwing (1966).
Drugs. The following drugs were used: atropine sulphate,
scopolamine hydrobromide, piracetam and physostig-
mine sulphate (Sigma). Drugs were dissolved, immedi-
ately before use, in isotonic (NaCl 0.9%) saline solution
and prepared in such a way that they could be
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administered in a volume of 10 mL/kg subcutaneously
(s.c.).
Statistical analysis. Results are given as the mean
 SEM; analysis of variance, followed by Scheffe’s F
procedure for post hoc comparison, was used to verify the
significance between two means. p values of less than
0.05 were considered significant. Data were analysed
with the StatView for Macintosh (1992) computer
program.
RESULTS
As shown in Fig. 1A the muscarinic antagonist
scopolamine injected i.p. at doses of 2 mg/kg was able
to disrupt the acquisition of a passive-avoidance condi-
tioned response in mice, as demonstrated by the short-
ening of the entry latency into the dark compartment
during the retention session. A similar cognition deficit
was obtained by hypoxia exposure (Fig. 1B). Atropine
(1–10 mg/kg s.c.) administered 20 min before the training
session, completely prevented the acquisition disruption
caused by both scopolamine and hypoxia. Atropine
injected s.c. at the same doses was not able to improve
learning in mice with any memory deficiency (Fig. 1).
Atropine (10 mg/kg s.c.) did not modify mouse sponta-
neous locomotor activity (Table 1) as proved by the
Animex test. Figure 1A, B also shows that under the same
experimental conditions the two well-known nootropic
drugs: piracetam (100 mg/kg i.p.) and physostigmine
(0.2 mg/kg i.p.) were able, as expected, to prevent
scopolamine and hypoxia amnesia. However, while
atropine and physostigmine did not modify learning in
mice free of memory impairment, piracetam reduced it.
DISCUSSION
The present study illustrates the paradoxical antiamnesic
activity of the antimuscarinic drug atropine. In agreement
with our results, other cholinomimetic effects of atropine
were previously observed by Ferguson-Anderson (1952)
and Brown (1990), who reported that in humans low
doses of atropine increased gastric contraction frequency
and amplitude and decreased heart rate. Bu¨lbring (1946)
and Ghelardini et al. (1990) described, respectively, the
ability of atropine to potentiate cholinergic transmission
in vitro at the isolated neuromuscular junction of rat
phrenic hemidiaphragm and in the longitudinal muscle
strip of guinea-pig.
The antiamnesic effect of atropine was obtained
without any cholinergic symptoms such as tremors,
scialorrhoea, diarrhoea, rhinorrhoea, lacrimation, abdo-
men flaccidity and also without any modification of
spontaneous activity or motor coordination, as demon-
strated by the Irwing test. On the other hand, physos-
tigmine, used at a dose equiantiamnesic with atropine,
provoked very clear cholinergic symptoms. The lack of
cholinergic side effects suggests that atropine acts as an
antiamnesic through a presynaptic mechanism. The
hypothesis of a presynaptic mechanism is supported by
the increase in endogenous ACh release induced by
atropine (Bartolini et al., 1994) at doses at which it
prevents scopolamine and hypoxia induced amnesia.
Furthermore, in the same range of doses atropine-induced
Figure 1. Effect of atropine, physostigmine and piracetam on
amnesia induced by scopolamine (2 mg/kg i.p.) (A) and
hypoxia (B) in the mouse passive avoidance test. ^p< 0.05.
*p< 0.01 in comparison with saline controls. Each column
represents the mean of 10±25 mice.
Table 1. Comparison of atropine and physostigmine in the Irwing test
Tremors Salivation Lacrimation Diarrhoea Abdominal tone
Spontaneous
motility
Saline s.c. 0 0 0 0 4 4
Atropine 10 mg/mL s.c. 0 0 0 0 4 4
Physostigmine 200 mg/mL s.c. 2 6 + + 2 0
Tremors absent = 0 maximum score = 8
Salivation absent = 0 maximum score = 8
Lacrimation absent = 0 present +
Diarrhoea absent = 0 present +
Abdominal tone ¯accid abdomen = 0 normal = 4 abdomen board-like = 8
Spontaneous motility absent = 0 normal = 4 maximum score = 8
Each value represents the mean of mice. Spontaneous motility was evaluated by Animex test.
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antinociception was antagonized by pretreatment with
the choline uptake depletor hemicholinium-3 (Ghelardini
et al., 1990). It is interesting to note that atropine elicits
its indirect cholinomimetic effects at doses 1000 times
lower than those able to provoke antimuscarinic effects,
such as amnesia, through the blockade of postsynaptic
receptors. The amplification of cholinergic responses
induced by atropine appears to be much more useful than
direct stimulation with cholinomimetic drugs such as
physostigmine. Direct stimulation with anticholines-
terases exerts a strong and continuous activation of
postsynaptic receptors responsible for a large series of
untoward effects at the same time as cognition facilita-
tion.
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